Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Pediatric Brain Tumor Consortium
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04295759CT.gov INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Oligodendroglioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Incb7839 (this asset) | Pediatric Brain Tumor Consortium | P1 | CC · 47 |
| Cediranib | National Cancer Institute (NCI) | P2 | BBB |
| Irinotecan | City of Hope Medical Center | P2 | BB |
| Trametinib | Novartis Pharmaceuticals | P4 | BB |
| Carboplatin | Oliver Jonas | P2 | BB |
| Dabrafenib | Novartis Pharmaceuticals | P4 | BB |
| Camustine | Shandong Lanjin Pharmaceuticals Co.,Ltd | P3 | BB |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | Andrew B Lassman, MD | P1/2 | B |
+42 more in the Anaplastic Oligodendroglioma cohort
Other indications for Incb7839
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P1/2 | CCC · 52 |
| Diffuse Intrinsic Pontine Glioma | — | P1 | CC · 47 |
| High Grade Astrocytic Tumor | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Incb7839 in Anaplastic Oligodendroglioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/incb7839-anaplastic-oligodendroglioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →